1446003-98-0

Upstream product

• 4720-83-6 6-oxabicyclo[3.2.1]oct-3-en-7-one 
• 76140-13-1 endo-4-iodo-6-oxabicyclo<3,2,1>octan-7-one 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 1772-03-8 D-(+)-galactosamine hydrochloride 
• 1374760-29-8 C₆₈H₈₁NO₁₆ 
• 1374760-28-7 C₇₀H₈₃NO₁₇ 
• 1374760-27-6 C₅₄H₆₃NO₁₅ 
• 1374760-26-5 C₄₇H₅₉NO₁₄ 
• 1374760-25-4 C₅₃H₆₅NO₁₇ 
• 1374760-24-3 C₁₈H₂₃Cl₃N₂O₁₀ 
• 1374760-22-1 C₁₈H₂₅NO₁₁ 
• 90-76-6 D-galactosamine 
• 1374760-21-0 C₃₇H₄₄O₈ 
• 1374760-20-9 C₁₆H₃₀O₄Si 

Relevant academic research and scientific papers

METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS

Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E- selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound.

E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation. These E-selection antagonists have the general formula (Ia) below.